Navigation Links
Joyant-Licensed Technology Earns Broad Patent Protection
Date:2/15/2011

DALLAS, Feb 15, 2011 /PRNewswire/ -- Joyant Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical company, announced the grant of an exceptional US patent covering an entire class of anti-cancer therapeutics based upon Smac mimetics.  Smac mimetics represent a novel approach to targeting the apoptotic pathway and have broad potential for the treatment of cancer, both solid tumor and hematological malignancies.

The United States Patent and Trademark Office (USPTO) granted US Pat. No. 7,884,211 on Joyant's exclusively-licensed anticancer drug technology.  "The USPTO issues broad claims like this only for truly pioneering inventions," noted Richard Aron Osman, JD, PhD, of the Science and Technology Law Group, the patent attorney responsible for prosecuting the patent application.

"Smac" is a natural protein that triggers the destruction of cancer cells. Researchers at UT Southwestern Medical Center serendipitously discovered that dimeric small molecule Smac mimics are extremely effective killers of cancer cells.  Joyant Pharmaceuticals, the exclusive licensee of this UT Southwestern technology, is actively developing Smac mimetics as anti-cancer therapeutics.

"We are very pleased with the scope of this issued patent.  It is a testament to the innovation and potential in our Smac mimetic program," said Dr. Lai Wang, Director of Research at Joyant.

"It is one of our most promising development platforms, with outstanding lead compounds."

About Joyant

Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Joyant is actively translating the molecular pathways that control the growth, replication, and apoptosis of human cells into signaling-based targeted therapeutics.  Joyant has the financial backing of Sanderling Ventures.


'/>"/>
SOURCE Joyant Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Proventix Helps Princeton Baptist Medical Center Earn National Recognition from HIMSS/ASQ for Quality Improvement Using Information Technology
2. Reportlinker Adds Global Anti-counterfeit Markets in Food & Pharmaceutical Applications by Geography, Technology Trends and Forecasts (2010-2015)
3. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
4. Abbotts Ibis Technology Identified Fatal Disease Organism in Afghanistan
5. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
6. Endologix Announces Favorable Clinical Results for Nellix Technology
7. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
8. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
9. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
10. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
11. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017 7D Surgical announced today ... the U.S. Food and Drug Administration (FDA) and ... the North American commercial launch of its innovative ... surgery, the 7D Surgical System.  ... technologies and machine vision algorithms to eliminate the ...
(Date:1/23/2017)... Research and Markets has announced the addition of the "Needle ... 2025" report to their offering. ... Report Highlights: The report provides a ... opportunities Market forecasts till 2025, using estimated market values ... business segments, Regions and Countries Key developments and strategies ...
(Date:1/23/2017)... , January 23, 2017 ... riñón (r enal) y el ... dosis de a pabetalone    Resverlogix ... los resultados preliminares de un ensayo en fase 1 ... discapacidad de riñón (renal) severa. Los datos demostraron unos ...
Breaking Medicine Technology:
(Date:1/23/2017)... ROSEMONT, IL (PRWEB) , ... ... ... Research and Education Foundation (OREF), in partnership with the American Society of ... Patient Safety Foundation (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and ...
(Date:1/23/2017)... ... 23, 2017 , ... “Crossing the Bar”: a moving and eloquent drama ... “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North Carolina ... credits the inspiration of the book to her sister, Denise, wishes to acknowledge her ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a ... Characteristics of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, ... thirteen years, a preacher for over nineteen, a pastor for over fifteen years. He ...
(Date:1/22/2017)... ... 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a ... retail buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam ... standards in all of its creations to help create a more traditional and natural ...
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
Breaking Medicine News(10 mins):